Clinical trials: SCHIZOPHRENIA 1 (Disorder)
Schizophrenia / Schizoaffective Disorder
NST-SPARK Open-Label Phase 1 STTR (IGNITE)
Schizophrenia Spectrum disorders (SSD) are among the most devastating psychiatric disorders. Prominent negative symptoms such as low motivation, anhedonia, asociality, and emotional flattening are experienced by up to 60% of…
- Trial name
- IGNITE (NCT07593456)
- Testing
- NST-SPARK
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- North Shore Therapeutics, Inc.
Schizophrenia
A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults
The purpose of the present trial is to obtain information on the absorption, distribution, metabolism, excretion and pharmacokinetics (PK) of 14C-SEP-380135 and its metabolites following a single oral dose.
- Trial name
- NCT07455084
- Testing
- 14C-SEP-380135
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
A 2-part, crossover design, open-label treatment trial with 4 periods, 4 sequences (Part A) to evaluate MR formulations of CVL-231 and a 2 periods, 2 sequences (Part B) to understand effect of food on CVL-231 exposures from an MR…
- Trial name
- NCT05106309
- Testing
- 10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Schizophrenia, Psychotic Disorders
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risperidone) and the investigators do within an…
- Trial name
- PAFIP3_1Y (NCT02532491)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Parasite and Infestation Physician-Patient Diagnostic Incongruency
The Parasite and Infestation Study
Many people have evidence of bugs, parasites, and infestation, but are told by others that they cannot find a cause. This distressing and frustrating experience can last for years, as the person seeks answers.
- Trial name
- NCT07849907
- Testing
- No intervention - observational study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia
Trial and Follow-up of the Efficacy of Two-stage Integrated Treatment for Chinese Schizophrenia Inpatients
Regular psychosocial intervention combined with antipsychotic drugs, compared with usual medication alone treatments, can reduce psychiatric symptoms and improve quality of life in patients with schizophrenia.
- Trial name
- NCT02850445
- Testing
- Olanzapine, Cognitive behavior therapy, Rehabilitation treatment
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Guangzhou Psychiatric Hospital
Schizophrenia
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants
- Trial name
- NCT02935725
- Testing
- Low dose AUT00206 800mg, High dose AUT00206 2000 mg, Ketamine
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Autifony Therapeutics Limited
Schizophrenia
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
- Trial name
- NCT00876304
- Testing
- PF-04802540
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
SCHIZOPHRENIA 1 (Disorder)
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
This is a Phase 2b, randomized, double-blind, parallel-group, active-controlled and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic…
- Trial name
- NCT07550387
- Testing
- HS-10380 Low Dose, HS-10380 Medium dose, HS-10380 High Dose
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia, Metabolic Syndrome
Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
- Conditions
- Schizophrenia, Metabolic Syndrome, Genetic Polymorphism
- Trial name
- NCT00717509
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National Hospital
Schizophrenia
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.
- Trial name
- NCT06345963
- Testing
- active H-coil delivered rTMS
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center, Houston
Bipolar 1 Disorder, Schizophrenia
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
The purpose of this study is to evaluate adherence to treatment with, and safety and tolerability of, the medical information device #1 (MIND1) system in subjects with Schizophrenia or Bipolar I Disorder who are currently treated…
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT01981811
- Testing
- Aripiprazole, Ingestible Event Marker (IEM)
- Where
- 12 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Digoxin Drug-Drug Interaction With Lurasidone HCl
The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.
- Trial name
- NCT01082289
- Testing
- Lurasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.
- Trial name
- PRISMA-1 (NCT01788774)
- Testing
- Risperidone ISM 50 mg, Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Where
- 5 sites in Croatia, Russia and 2 more
- Volunteers
- 36 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia, Schizoaffective Disorder
Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging
The goal of the project is to characterize abnormalities in brain structure and function related to schizophrenia. The investigators will use advanced magnetic resonance imaging (MRI) techniques to measure the degree and…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Hallucinations
- Trial name
- NCT00288340
- Testing
- functional magnetic resonance imaging
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Schizophrenia, Schizoaffective Disorder
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.
- Trial name
- NCT02636842
- Testing
- Aripiprazole Lauroxil
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alkermes, Inc.
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2
In Study 2, investigators will recruit individuals with schizophrenia (SZ) and or schizoaffective disorder (SZA) and healthy controls (HC) using optimized behavioral tasks to replicate the behavioral findings from Study 1 and to…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder, Healthy Adult
- Trial name
- CNTRACS 2 (NCT07875790)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Schizoaffective
Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI).
- Conditions
- Schizophrenia, Schizoaffective, Bipolar Disorder 1
- Trial name
- ESHANTI (NCT05157620)
- Testing
- Yoga-based Exercise (YE), Wellness Lifestyle Program (WLP)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- VA Office of Research and Development
Auditory Hallucination, Hearing Voices When No One is Talking
Imagery Interventions for Auditory Vocal Hallucinations
This study explores the feasibility, acceptability, and effectiveness of four imagery intervention techniques (metacognitive imagery intervention, imagery rescripting, promoting positive imagery and competing imagery task) for…
- Conditions
- Auditory Hallucination, Hearing Voices When No One is Talking, Psychosis
- Trial name
- NCT05603260
- Testing
- Imagery intervention for voice hearing (meta-cognitive imagery rescripting), Imagery intervention for voice hearing (Imagery rescripting), Imagery intervention for voice hearing (promoting positive imagery de novo)
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Hella Janssen
Schizophrenia, Bipolar I Disorder
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
- Trial name
- NCT05648591
- Testing
- Iloperidone
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vanda Pharmaceuticals